Abstract
Rationalization of therapy in rheumatology has huge potential benefits. Daniel Furst is at the forefront of those seeking to improve the ways that change can be measured in rheumatic diseases in order to provide optimal therapy. Furst also led the OPPOSITE trial and published the findings earlier this year. Furst is the Carl M Pearson Professor of Medicine and Director of the Rheumatology Clinical Research Center at the University of California, Los Angeles (UCLA), CA, USA. He received his medical degree from Johns Hopkins University, MD, USA, in 1968 and completed fellowships in Clinical Pharmacology at the University of California, San Francisco and in Rheumatology at UCLA. His research interests are in the clinical pharmacology of drugs used to treat rheumatic and autoimmune diseases, including nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs and biological modifiers. Here he discusses the approaches towards rationalizing therapy and highlights some future directions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
